Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Merger or Acquisition (December 2024)
21 slides from Cohance Lifesciences's merger presentation, Dec 7, 2024
Slide 1: Cover letter to stock exchanges
December 7, 2024 To To The Manager The Manager Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543064 Scrip
Slide 2: Press Release: Suven to acquire controlling stake in NJ Bio
Suven to acquire controlling stake in NJ Bio, Inc., an ADC specialist player; Further strengthens Suven’s position as a Technology-led CDMO Suven acquires a 56% stake in NJ Bio at a US$100mn pre-money valuation, investing US$64.4mn, including US$15mn for growth initiatives • Transaction enhances Suv
Slide 3: Press Release: Transaction Highlights
Transaction Highlights: • Investment: Suven will acquire 56% stake in NJ Bio (pre-money valuation of US$100mn) through a combination of primary and secondary: - US$49.4mn for buying out the existing minority shareholders - US$15mn as primary equity infusion; will be mainly used for capex (GMP expans
Slide 4: Acquisition conference call details
Acquisition conference call details Suven Pharmaceuticals Ltd will conduct a conference call to discuss NJ Bio majority stake acquisition. The management team will be represented by Mr. Vivek Sharma (Executive Chairman), Dr. V Prasada Raju (Managing Director), Dr. Sudhir Kumar Singh (Chief Executive
Slide 5: Suven Pharmaceuticals Ltd. - Technology focused acquisition
Suven Pharmaceuticals Ltd. Going Above and Beyond Investor Presentation – Technology focused acquisition – majority stake in NJ Bio Inc.
Slide 6: Safe Harbour
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these fo
Slide 7: Business Overview
eo EO = > a ® -@ ex *- Business Overview
Slide 8: NJ Bio at a Glance
NJ Bio at a Glance End-to-end capabilities: Headquartered in ADC / XDC focused ~US$32mn sales in Founded in late 2017 Linker, Payload, ~140 employees Princeton, US CRDMO CY24e Bioconjugation, Analytical Founder is a very well-renowned scientist in the ADC Established a successful CRDMO within few ye
Slide 9: NJ Bio Business – End to end ADC/XDC capabilities
NJ Bio Business – End to end ADC/XDC capabilities Revenue Growth Trajectory2 Business and service offerings (US$mn) • End-to-end ADC chemistry capabilities (P-L1 synthesis, bioconjugation, bioanalytical services). Also has capabilities in the broader XDC segment (radio conjugates, oligo conjugates,
Slide 10: Investment Thesis
Investment Thesis Transaction further strengthens Suven’s position as a Technology-led CDMO with end-to-end capabilities in ADC chemistry Expands Suven’s addressable Enhances Suven’s domain Founder & team have deep ADC market in the fast-growing (20%+ expertise in ADC with expanded expertise CAGR) A
Slide 11: Builds on Platform's Existing ADC Presence & Provides Entry into Next Gen XDCs
Builds on Platform’s Existing ADC Presence & Provides Entry into Rapidly Growing Next Gen XDCs. We can Provide Full Suite of ADC Chem Services Across Lifecycle 1 ADC Manufacturing Process 3 India + US footprint Monoclonal Linker & P/L Bio- Payload Fill-Finish Antibody synthesis conjugation Suven Pla
Slide 12: ADC is amongst the Fastest Growing Modalities
ADC is amongst the Fastest Growing Modalities; Transaction Expands Suven’s Addressable Market in the Fast-growing ADC/XDC CDMO Segment ADC therapeutics market is expected to demonstrate sustained high Suven Platform and NJ Bio’s relevant addressable growth market is slated to grow from $1.4B to $4B
Slide 13: Multiple avenues of synergies between NJ Bio and Suven Platform
Multiple avenues of synergies between NJ Bio and Suven Platform NJ Bio Suven Synergies • Deep know-how in end to ✓ Transforms Suven Platform into a end ADC and broader XDCs • Backward integrated in major ADC player providing deep Technology (payload-linker synthesis, Camptothecin class of tech capab
Slide 14: Transaction Overview
lod *< Transaction Overview
Slide 15: Transaction Overview
Transaction Overview • NJ Bio is valued at US$100mn pre-money Equity value • Suven will own a 56% stake in NJ Bio through a combination of acquiring stake from existing minority shareholders and Valuation and infusing growth equity capital Key - US$49.4mn for buying 49.4% stake from existing minorit
Slide 16: The ADC Segment
‘¥BIO The ADC Segment
Slide 17: Building blocks of Antibody Drug Conjugates (ADC) and Mechanism of Action
Building blocks of Antibody Drug Conjugates (ADC) and Mechanism of Action Rapidly growing class of drugs intended at targeted delivery of highly potent and cytotoxic agents selectively to tumor tissue Exploring ADC composition • Antibody (mAB) is the targeting component of an ADC. It must be highly
Slide 18: Transforming Therapies: Rapid expansion of ADC R&D Pipelines
Transforming Therapies: Rapid expansion of ADC R&D Pipelines ADCs / XDCs as a class continue to see strong growth in R&D investments, providing strong foundation for CRDMO market Active programs by phase (2024) Total Total ADCs XDCs • ~750 active ADC / XDC programs in clinics or in preclinical phase
Slide 19: Expansion of ADC - CDMO Market share via NJ Bio
Expansion of ADC - CDMO Market share for Suven+Cohance platform via NJ Bio Suven’s Addressable Market expands 7x (US$200mn to US$1.4bn), post-acquisition. Suven Platform and NJ Bio’s relevant addressable market is slated to grow from US$1.4bn to US$4bn (23%+ CAGR) Addressable market size(US$1.36Bn)
Slide 20: Contact Information
Contact Information Cyndrella Carvalho, Head - Investor Relations, Suven Pharmaceutical Ltd Tel: +91 9823615656 Email: cyndrella.carvalho@suvenpharm.com Gavin Desa / Rishab Barar CDR - India Tel: +91 98206 37649/ +91 77770 35061 Email: gavin@cdr-india.com / rishab@cdr-india.com Pg. 16
Slide 21: Thank You
_— ; SUVEN cohance N}BIO PHARMA integrated Chemisty Senice Provide:
Cohance Lifesciences — Merger or Acquisition (December 2024) on 6ix